These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8970007)

  • 21. The epidemiology of Parkinson's disease in the county of Rogaland, Norway.
    Tandberg E; Larsen JP; Nessler EG; Riise T; Aarli JA
    Mov Disord; 1995 Sep; 10(5):541-9. PubMed ID: 8552103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR image texture in Parkinson's disease: a longitudinal study.
    Sikiö M; Holli-Helenius KK; Harrison LC; Ryymin P; Ruottinen H; Saunamäki T; Eskola HJ; Elovaara I; Dastidar P
    Acta Radiol; 2015 Jan; 56(1):97-104. PubMed ID: 24413223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance relaxometry in Parkinson's disease.
    Mondino F; Filippi P; Magliola U; Duca S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S87-8. PubMed ID: 12548357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of tremor onset on middle cerebellar peduncle of Parkinson's disease.
    Sako W; Murakami N; Miyazaki Y; Abe T; Harada M; Izumi Y; Kaji R
    J Neurol Sci; 2015 Nov; 358(1-2):172-7. PubMed ID: 26341153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.
    Cho ZH; Oh SH; Kim JM; Park SY; Kwon DH; Jeong HJ; Kim YB; Chi JG; Park CW; Huston J; Lee KH; Jeon BS
    Mov Disord; 2011 Mar; 26(4):713-8. PubMed ID: 21506148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
    Martin WR; Wieler M; Gee M
    Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic Restless Legs Syndrome.
    Zhu XY; Liu Y; Zhang XJ; Yang WH; Feng Y; Ondo WG; Tan EK; Wu YC
    J Neurol Sci; 2015 Oct; 357(1-2):109-14. PubMed ID: 26189051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy.
    Matsuura K; Maeda M; Yata K; Ichiba Y; Yamaguchi T; Kanamaru K; Tomimoto H
    Eur Neurol; 2013; 70(1-2):70-7. PubMed ID: 23796701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.
    Williams DR; Lees AJ
    Lancet Neurol; 2005 Oct; 4(10):605-10. PubMed ID: 16168928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.
    Maier F; Merkl J; Ellereit AL; Lewis CJ; Eggers C; Pedrosa DJ; Kalbe E; Kuhn J; Meyer TD; Zurowski M; Timmermann L
    Parkinsonism Relat Disord; 2014 Apr; 20(4):421-7. PubMed ID: 24467817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
    Stiasny-Kolster K; Doerr Y; Möller JC; Höffken H; Behr TM; Oertel WH; Mayer G
    Brain; 2005 Jan; 128(Pt 1):126-37. PubMed ID: 15548552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
    Gerschlager W; Bencsits G; Pirker W; Bloem BR; Asenbaum S; Prayer D; Zijlmans JC; Hoffmann M; Brücke T
    Mov Disord; 2002 May; 17(3):518-23. PubMed ID: 12112200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A deformation-based morphometry study of patients with early-stage Parkinson's disease.
    Borghammer P; Østergaard K; Cumming P; Gjedde A; Rodell A; Hall N; Chakravarty MM
    Eur J Neurol; 2010 Feb; 17(2):314-20. PubMed ID: 19912319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.
    Berardelli A; Wenning GK; Antonini A; Berg D; Bloem BR; Bonifati V; Brooks D; Burn DJ; Colosimo C; Fanciulli A; Ferreira J; Gasser T; Grandas F; Kanovsky P; Kostic V; Kulisevsky J; Oertel W; Poewe W; Reese JP; Relja M; Ruzicka E; Schrag A; Seppi K; Taba P; Vidailhet M
    Eur J Neurol; 2013 Jan; 20(1):16-34. PubMed ID: 23279440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the prevalence of Parkinson's disease using dopamine transporter imaging.
    Kim JM; Kim JS; Kim KW; Lee SB; Park JH; Lee JJ; Kim YK; Kim SE; Jeon BS
    Neurol Res; 2010 Oct; 32(8):845-51. PubMed ID: 20021740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychiatric symptoms in Parkinson's disease: fronto-striatal atrophy contributions.
    O'Callaghan C; Shine JM; Lewis SJ; Hornberger M
    Parkinsonism Relat Disord; 2014 Aug; 20(8):867-72. PubMed ID: 24866458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnosis of manganese-induced parkinsonism.
    Cersosimo MG; Koller WC
    Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.